$3200 | Single User
$4200 | Site License
$6000 | Enterprise License

Poly(adenosine diphosphate [ADP]–ribose) Polymerases (PARPs) Inhibitors
Successful targeting of DNA Repair Pathways by PARP Inhibitors – Current and Future Potential [Report Updated: 28-07-2017]

Published by ProGrow Pharma Partners: 28 Jul 2017 | 107360 | In Stock

Introduction

Poly(adenosine diphosphate [ADP]–ribose) polymerases (PARPs) activity is essential for the repair of damaged DNA. The DNA repair pathway is defective/mutated in several cancers (BRCA1, BRCA2 ovarian and breast cancer, etc) and further impairing this pathway by PARP inhibitors in these cancers is the basis of developing DNA repair targeted therapies. In the Last four years three drugs targeting PARPs have been approved for Ovarian Cancer (BRCA mutant) and new clinical data supports further label expansion of this class of drugs in other solid tumors. PARP inhibitors have demonstrated clear patient benefit in germline BRCA (gBRCA), Homologous Recombination (HR)-deficient, and other ovarian cancers. The market opportunity of this class of drug in the approved Ovarian cancer indication itself is large and the best is yet to come from the label expansion in other cancers- Prostate, Breast, Lung, Endometrial, Pancreatic, GlioBlastoma Multiforme (GBM), , etc. as a monotherapy or in combination with other targeted drugs. The innovator companies have pegged the market opportunity of this class of drugs beyond bn which should trigger M&A activity at attractive terms for them. In this report, we highlight the rationale of inhibiting PARP in different cancers and the promising clinical data. Clinical progress of PARP inhibitors as a monotherapy against tumors with existing DNA repair defects, such as BRCA1 and BRCA2 and other mutations, and as a combination therapy when administered with other targeted therapies as well as chemotherapeutics that induce DNA damage.

Table of Contents
for Poly(adenosine diphosphate [ADP]–ribose) Polymerases (PARPs) Inhibitors Successful targeting of DNA Repair Pathways by PARP Inhibitors – Current and Future Potential [Report Updated: 28-07-2017]

  • TABLE OF CONTENTS

    1. Executive Summary 4

    2. Overview of PARP Inhibitors 6

    3. Strategy Used in developing PARP Inhibitors as drugs – Turning Mutations against the Cancer Cells 8

    4. Competitive Landscape – PARP inhibitors-drugs in pipeline 9

    5. Potential of PARP Inhibitors set to Unfold! 11

    6. PARP Inhibitors in Approved Indication- Ovarian Cancer 13

    • Current Treatment options in Ovarian Cancer 14

    • PARP Inhibitors in Ovarian Cancer 14

    • Clinical data and future Label Expansion in Ovarian Cancer 15

    • Ongoing clinical trials in Ovarian cancer 19

    7. Breast Cancer 21

    8. Prostate Cancer 22

    9. Lung Cancer – Non-Small Cell Lung Cancer (NSCLC) 23

    10. Other Cancers 24

    • Pancreatic Cancer 24

    • Endometrial Cancer 25

    • Brain Tumors- GBM 25

    • Gastric Cancer 26

    11. Commercial Outlook 27

    12. M & A Opportunity 29

    13. Key Milestones 31

    14. Appendix I – Ovarian Cancer – Ongoing Clinical Trials 33

    15. Appendix II – Breast Cancer – Ongoing Clinical Trials 40

    16. Appendix III – Prostate Cancer – Ongoing Clinical Trials 45

    17. Appendix IV – Lung Cancer – Ongoing Clinical Trials 47

    18. Appendix V – Other Cancers (Pancreatic, Endometrial, Gastric, GBM, etc.) – Ongoing Clinical Trials 49

List Of Tables
in Poly(adenosine diphosphate [ADP]–ribose) Polymerases (PARPs) Inhibitors Successful targeting of DNA Repair Pathways by PARP Inhibitors – Current and Future Potential [Report Updated: 28-07-2017]

Table 1a PARP Inhibitors: Drugs – Approved and in the Pipeline for Solid Tumors 9-10

Table 1b Comparative in vitro and Other Preclinical Properties of Select PARP Inhibitors 10

Table 2 Comparative Clinical Efficacy and Safety data of Approved PARP inhibitors in Recurrent Advanced Ovarian Cancer 16-18

Table 3 Future Market Potential of PARP inhibitors 27

Table 4 Historical M&A and Licensing Deals for PARP inhibitors 30

Appendix

I Ovarian Cancer – Ongoing Clinical Trials 33-39

II Breast Cancer – Ongoing Clinical Trials 40-44

III Prostate Cancer – Ongoing Clinical Trials 45-46

IV Lung Cancer – Ongoing Clinical Trials 47-48

V Other Cancers (Pancreatic, Endometrial, Gastric, GBM etc.) – Ongoing Clinical Trials 49-56

List Of Figures, Charts and Diagrams
in Poly(adenosine diphosphate [ADP]–ribose) Polymerases (PARPs) Inhibitors Successful targeting of DNA Repair Pathways by PARP Inhibitors – Current and Future Potential [Report Updated: 28-07-2017]

Figure 1A: DNA Repair Pathways 7

Figure 1B: PAPR Inhibitors Drive Synthetic Lethality 7

Figure 2: Rationale for targeting BRCA and Other Mutations by PARP in Solid Tumors 12

Figure 3: Better Therapies for Ovarian Cancer in the Next Five Years 19

Figure 4: Leading sites of Cancer Cases and Deaths – 2017 Estimates: US 28

Figure 5: Leading sites of Cancer Cases and Deaths Estimates: Worldwide 29

Additional Details

Publisher

ProGrow Pharma Partners

Publisher Information

ProGrow Pharma Partners – Company Profile



ProGrow Pharma (PGP) Partners is an advisory firm with a team of professionals having more than a decade of experience in serving the Pharmaceutical Industry.  Team @ PGP has an in-depth understanding of the science and challenges associated with innovation, drug development, clinical trials, patents & litigations and competition across geographies, and competitive landscape in specific therapy, molecular target, or diseases. 



Our exclusive focus and knowledge of the Global Biotech, and Healthcare sector enables us to offer advisory services to healthcare companies (Market leaders, Innovators, Generic Players CROs and others ) and its Investors (Private Equity investors, Venture Capitalists, HNIs and others).  Our research and domain knowledge support the clients in making strategic decisions to accelerate the growth of the company.  

Reference

107360 | -

Number of Pages

56

Report Format

PDF

ProGrow Pharma Partners Reports

Related Reports

TitleDate PublishedPrice fromMore Details
Poly [ADP Ribose] Polymerase 2 (ADP Ribosyltransferase Diphtheria Toxin Like 2 or NAD(+) ADP Ribosyltransferase 2 or Poly[ADP Ribose] Synthase 2 or PARP2 or EC 2.4.2.30) - Pipeline Review, H1 2017
Poly [ADP Ribose] Polymerase 2 (ADP Ribosyltransferase Diphtheria Toxin Like 2 or NAD(+) ADP Ribosyl...
30 May 2017 by Global Markets Direct USD $3,500 More Info
Personal Care Encapsulation Materials Market by Material Type (Polysaccharides (Gums, Starches, Celluloses, Cyclodextrines, Chitosan), Proteins (Gelatin, Casein, Soy Proteins), Lipids (Waxes, Paraffin, Oils), Synthetic Polymers (Acrylic Polymers, Polyvinyl Alcohol, Poly(vinylpyrrolidone)), and Application (Shower and Bath Gels, Color Cosmetics, Wrinkle Creams, Soaps, Aromatherapy Products) - Korea
The Korean personal care encapsulating materials market is expected to reach ,880 thousand by 202...
01 Apr 2017 by Allied Market Research USD $2,850 More Info
Poly Medicure Limited (POLYMED) - Financial and Strategic SWOT Analysis Review
Poly Medicure Limited (POLYMED) - Financial and Strategic SWOT Analysis Review provides you an in-de...
27 Sep 2016 by Global Data USD $125 More Info
Poly Medicure Limited (POLYMED) - Financial and Strategic SWOT Analysis Review
Poly Medicure Limited (POLYMED) - Financial and Strategic SWOT Analysis Review provides you an in-de...
23 Aug 2016 by Global Data USD $125 More Info
Medical Adhesives Market - By Natural Resin Type (Collagen, Fibrin, Albumin); Synthetic & Semi Synthetic Type (Acrylic, Cyanoacrylate, Epoxy, Silicone, Poly Ethylene Glycol,) Formulating Technology (Water, Solid & Hot Melt & Solvent Based) - Forecast 2016-2021.
The adhesives used in the medical applications are one of the important segments in the chemical ind...
11 Apr 2016 by Industry ARC USD $5,250 More Info
Poly Medicure Limited (POLYMED) - Financial and Strategic SWOT Analysis Review
Poly Medicure Limited (POLYMED) - Financial and Strategic SWOT Analysis Review provides you an in-de...
05 Apr 2016 by Global Data USD $125 More Info
Pour Point Depressant Market - By Types (Polyalkyl Methacrylates, Styrene Esters, Poly Alpha olefins and Others); By Industry (Marine, Automotive, Aviation, Oil & Gas and Others); By Geography - Forecast (2016-2021)
The pour point of a fuel can be termed as the lowermost temperature at which it is likely to decant ...
12 Jan 2016 by Industry ARC USD $5,250 More Info
3D Printing Gases Market by Type (Argon, Nitrogen), Technology (Stereo lithography, Laser Sintering, Poly-Jet), Storage & Distribution (Cylinder, Merchant Liquid, Tonnage), Function (Insulation, Illumination, Cooling), End User (Design & Manufacturing, Healthcare) - Forecast to 2020
“Increasing demand for healthcare to drive the 3D printing/additive manufacturing gases market.” The...
15 Dec 2015 by MarketsandMarkets USD $7,150 More Info
Pour Point Depressants Market by Chemistry (polyalkylmethacrylates, styrene esters, ethylene co vinyl acetate, poly alpha olefin, and others), by End User (Lubricant Industry and Oil & Gas Industry) & by region - Global Trends & Forecasts to 2020
Pour point is the lowest temperature at which fluid can flow freely under standard conditions. At lo...
24 Jul 2015 by MarketsandMarkets USD $5,650 More Info
Fluoropolymer Coatings Market: Type (Poly Tetra Fluor Ethylene (PTFE), Poly Vinylidene Di Fluoride (PVDF), Per Fluor Alkoxy, Others) Application (Metals, Non-Metals) Industries (Food Processing, Textiles, Medical, Aerospace, Others)-Forecast (2017-2022)
Fluoropolymer coatings are amalgamation of high performance resins and fluoropolymer lubricants that...
17 Jun 2015 by Industry ARC USD $5,250 More Info

This report is published by ProGrow Pharma Partners

ProGrow Pharma Partners – Company Profile

ProGrow Pharma (PGP) Partners is an advisory firm with a team of professionals having more than a decade of experience in serving the Pharmaceutical Industry.  Team @ PGP has an in-depth understanding of the science and challenges associated with innovation, drug development, clinical trials, patents & litigations and competition across geographies, and competitive landscape in specific therapy, molecular target, or diseases. 

Our exclusive focus and knowledge of the Global Biotech, and Healthcare sector enables us to offer advisory services to healthcare companies (Market leaders, Innovators, Generic Players CROs and others ) and its Investors (Private Equity investors, Venture Capitalists, HNIs and others).  Our research and domain knowledge support the clients in making strategic decisions to accelerate the growth of the company.  

Download Free Report Summary PDF

Poly(adenosine diphosphate [ADP]–ribose) Polymerases (PARPs) Inhibitors
Successful targeting of DNA Repair Pathways by PARP Inhibitors – Current and Future Potential [Report Updated: 28-07-2017] | Download PDF Summary

Download our FREE report summary PDF. It contains all the information on these web pages, plus a Proforma Invoice request form, should you need it to satisfy your company's internal order procedures.

Ordering Information

Orders are processed immediately and you will be notified of the despatch date on confirmation of your order.

Accepted Card Types

Payment

Buy now using our secure payment system.

We Stock...

  • Allied Market Research
  • CBR Pharma
  • Current Partnering
  • Firstword
  • Global Data
  • Global Markets Direct
  • ICD Research
  • Infinti Research Technavio
  • Marketline
  • Markets and Markets
  • Micro Markets Monitor
  • MP Advisors
  • Venture Planning Group
  • GMR Data